Federated Hermes’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-918,500
| Closed | -$69.1M | – | 2297 |
|
|
2022
Q2 | $69.1M | Sell |
918,500
-1,156,537
| -56% | -$51.4M | 0.19% | 144 |
|
|
2022
Q1 | $55.7M | Buy |
2,075,037
+341,455
| +20% | +$11.5M | 0.13% | 211 |
|
|
2021
Q4 | $82.7M | Buy |
1,733,582
+183,199
| +12% | +$8.19M | 0.15% | 183 |
|
|
2021
Q3 | $103M | Buy |
1,550,383
+354,953
| +30% | +$25.3M | 0.2% | 145 |
|
|
2021
Q2 | $93.3M | Buy |
1,195,430
+222,244
| +23% | +$16.4M | 0.17% | 161 |
|
|
2021
Q1 | $92.1M | Buy |
973,186
+159,724
| +20% | +$19M | 0.18% | 154 |
|
|
2020
Q4 | $99.1M | Buy |
813,462
+180,050
| +28% | +$19.7M | 0.2% | 125 |
|
|
2020
Q3 | $55.3M | Buy |
633,412
+26,330
| +4% | +$1.83M | 0.13% | 188 |
|
|
2020
Q2 | $39.2M | Buy |
607,082
+182,972
| +43% | +$10.6M | 0.1% | 246 |
|
|
2020
Q1 | $18.9M | Buy |
424,110
+24,110
| +6% | +$1.28M | 0.06% | 344 |
|
|
2019
Q4 | $24.9M | Hold |
400,000
| – | – | 0.06% | 354 |
|
|
2019
Q3 | $15M | Buy |
400,000
+109,600
| +38% | +$4.77M | 0.04% | 440 |
|
|
2019
Q2 | $11.8M | Buy |
+290,400
| New | +$10.4M | 0.03% | 520 |
|
Federated Hermes's TPTX Position: Q3 2022 in Review
Federated Hermes sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 918,500 shares — an estimated $69.1M sold.
Federated Hermes first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $103M in Q3 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Federated Hermes reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Federated Hermes sold 918,500 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $69.1M.
- Federated Hermes first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Federated Hermes's Turning Point Therapeutics, Inc. Common Stock position peaked at $103M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Federated Hermes's 13F filing for Q3 2022, filed 14 Nov 2022.